Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
22 avr. 2024 07h30 HE
|
Kura Oncology, Inc.
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to...
Kura Oncology to Participate in Stifel Targeted Oncology Forum
10 avr. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 avr. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
06 mars 2024 07h30 HE
|
Kura Oncology, Inc.
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of KO-2806 as a monotherapy continues in parallel – SAN DIEGO, March ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 mars 2024 17h00 HE
|
Kura Oncology, Inc.
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
27 févr. 2024 16h01 HE
|
Kura Oncology, Inc.
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008...
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
26 févr. 2024 07h30 HE
|
Kura Oncology, Inc.
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML – SAN DIEGO, Feb. 26, 2024 (GLOBE...
Kura Oncology to Participate in Three Upcoming Investor Conferences
22 févr. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
20 févr. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 févr. 2024 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...